Evidence map›Paper›PMID 38781434›Full record

ArticleEuropean journal of endocrinology2024

Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis.

Dongyun Zhang, Willy Hugo, Marvin Bergsneider, Marilene B Wang, Won Kim, Karam Han, Harry V Vinters, Anthony P Heaney

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Journal of the Endocrine Society · 2026
    Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dongyun ZhangDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Willy HugoDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Marvin BergsneiderDepartment of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Marilene B WangDepartment of Head and Neck Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Won KimDepartment of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Karam HanDepartment of Pathology and Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Harry V VintersDepartment of Pathology and Lab Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Anthony P HeaneyDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0003-3865-0810

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discoveryR01CA251930 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HEANEY, ANTHONY P · 2021 to 2025
$1.8M
Development of a patient-derived tumoroid culture system to explore novel medical treatments for refractory prolactinomasR21CA264838 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HEANEY, ANTHONY P · 2023 to 2024
$392k
National Cancer Institute NIH/NCI R01CA251930NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA251930NCI NIH HHS R21 CA264838NIH/NCI R21CA264838Warley Trust
6 · The paper itself

Abstract

objectiveUnravel the potential mechanism(s) of the on- and off-target actions of dopamine agonist therapy in both human prolactinoma tumors and neighboring stromal and immune cells. DESIGN AND

methodsFive surgically resected prolactinomas (PRLomas) from 3 cabergoline (CBG)-treated patients and 2 treatment-naive patients were analyzed by using single-cell RNA sequencing (scRNA-seq) to compare the cellular composition and transcriptional landscape.

resultsSix major cell populations, namely tumor (88.2%), immune (5.6%), stromal (4.9%), progenitor cells (0.6%), proliferating cells (0.4%), and erythrocytes (0.2%), were observed. Tumor cells from CBG-treated patients expressed lower levels of genes that regulated hormone secretion, such as SCG2, VGF, TIMP1, NNAT, and CALD1, consistent with the inhibitory effects of CBG on hormone processing and secretion. Interestingly, we also observed an increased number of CD8+ T cells in the CBG-treated tissues. These cytotoxic CD8+ T cells expressed killing granule components such as perforin and the granzymes GZMB, GNLY, and KLRD1 as well as the inflammatory cytokine CCL5. Immune cell activation of these CD8+ T cells was further analyzed in a compartment-specific manner, and increased CD25 (IL2R) expression was noted in the CD8+ T cells from the CBG-treated samples. Additionally, and confirming prior reports, we noted a higher stromal cell population in the CBG-treated samples.

conclusionsOur scRNA-seq studies revealed key differences in the transcriptomic features of CBG-treated and CBG-untreated PRLomas in both tumor and microenvironment cellular constituents, and for the first time, describe the previously unknown activation of CD8+ T cells following CBG treatment, which may play a role in the tumoricidal actions of CBG.

Indexed as

CabergolinePituitary NeoplasmsProlactinomaAdultCD8-Positive T-LymphocytesDopamine AgonistsFemaleFibrosisHumansMaleMiddle AgedProlactinStromal CellsTumor MicroenvironmentYoung AdultCabergolineDopamine AgonistsProlactincabergolinepituitary tumorprolactinomasscRNA-seqtumor microenvironment

Identifiers

PMID38781434
PMCPMC12054100

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.